Opendata, web and dolomites

TLA-Gut SIGNED

Novel Personalized Cellular Therapy Approach for Immune Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TLA-Gut project word cloud

Explore the words cloud of the TLA-Gut project. It provides you a very rough idea of what is the project "TLA-Gut" about.

blood    completion    commercialisation    caused    gap    rate    praxis    exists    therapies    karolinska    tissues    aligned    commercialise    efficacy    enabler    treat    cells    direct    bowel    clinicians    treatments    healthcare    cytokines    first       sweden    close    causing    proof    group    patient    inflammation    positioned    belongs    date    tla    remission    stockholm    opportunity    poses    shown    removing    patients    clinical    risk    therapeutic    billion    gut    imids    globally    treatment    inflammatory    safe    regulatory    triggered    maintained    strategy    induce    remaining    economic    option    burden    therapy    ibd    personalized    efficient    vivo    migrate    leukapheresis    internationally    device    diseases    performed    release    chemotaxis    institutet    imbalance    demand    trial    proven    socio    once    exaggerated    life    60    disease    business    satiate    threatening    site    market    create    mediated    medical    carry    immune   

Project "TLA-Gut" data sheet

The following table provides information about the project.

Coordinator
TLA TARGETED IMMUNOTHERAPIES AB 

Organization address
address: EKONOMILANKEN AB BOX 726
city: SOLLENTUNA
postcode: 191 27
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.tlatherapies.com/
 Total cost 3˙850˙000 €
 EC max contribution 2˙695˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TLA TARGETED IMMUNOTHERAPIES AB SE (SOLLENTUNA) coordinator 2˙695˙000.00

Map

 Project objective

This project will commercialise TLA Gut - the novel medical device for the treatment of Inflammatory Bowel Disease (IBD). IBD belongs to the group of Immune Mediated Inflammatory Diseases (IMIDs) caused and maintained by an exaggerated inflammatory response triggered by an imbalance of the immune system. Research at Karolinska Institutet in Sweden has shown that IMIDs are caused by increase in specific inflammatory cells, which migrate to the site of inflammation by chemotaxis and induce disease-causing inflammation through release of cytokines in tissues. TLA Gut is a globally unique technology, and the first medical device with a proven clinical efficacy in removing those disease-causing cells from the blood of the patient through therapeutic leukapheresis. Today, the development and commercialisation of new therapies for IBD is in great demand among clinicians and their patients as current treatments offer an overall long-term remission rate of only 50-60% and carry the risk of life-threatening side effects. There exists a strong business opportunity for a therapy that would create a new and personalized way to treat IBD. TLA Gut is positioned to satiate this demand. To date, TLA Gut in vivo proof of concept has been established in a Phase I/II clinical trial on IBD patients in Stockholm. In the project, the Phase III study will be performed together with regulatory development work required to get market access upon completion of the project. IBD poses a significant socio-economic burden internationally. In Europe, a direct healthcare cost of IBD is estimated to € 4.6–5.6 billion per year. Once introduced in the clinical praxis across the EU, TLA Gut will be a safe and cost-efficient treatment option for IBD patients. The overall business strategy of TLA is aligned to close the remaining clinical and regulatory gap to the market for TLA Gut and commercialise the medical device. The project is the key enabler of this strategy.

 Deliverables

List of deliverables.
Project website created and launched Websites, patent fillings, videos etc. 2019-11-14 10:13:28

Take a look to the deliverables list in detail:  detailed list of TLA-Gut deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TLA-GUT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TLA-GUT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More